While studying GLP-1s and how effectively they treat diabetes, researchers discovered how significantly these medications can also affect a persons appetite, satiety, and food intake
We want their leptin sensitive
That follow-up trial, involving 536 obese adults over 24 weeks, failed to meet its primary efficacy endpoint, meaning the fat-loss effect seen at the smaller scale did not hold up in the pivotal study
So, pharmaceutical companies started investigating the use of GLP-1s for weight-management purposes, and the first GLP-1 weight-loss drug, Saxenda (liraglutide), was approved by FDA in 2014 (it was previously approved to treat diabetes under the name Victoza)
The deadline for stopping production and distribution of compounded tirzepatide passed in March